Podduturu Reddy
Pulmonary Disease · Port Huron, MINPI 1003816331
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $224,264 of the $324,390 with a category attached, or 69.1%. 37 manufacturers reported payments, led by AstraZeneca at 49.9% of the total. Reporting peaked in 2019 at $141,905 and has fallen 79.7% since, to $28,807 in 2025. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 799 payments — averaging $406.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$162K
- Genentech USA, Inc.$114K
- Amgen$19K
- Regeneron Healthcare Solutions, Inc.$18K
- Sanofi$4K
- Novartis$3K
- plus $5K from 31 others
Across 4 payments — averaging $2834.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$11K
What the payments were for
- Consulting fees$29,7209%
- Speaking & faculty fees$224,26469%
- Travel & lodging$49,16815%
- Food & beverage$21,1707%
- Education$690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 284 | $161,917 |
| Genentech USA, Inc. | 154 | $114,438 |
| Amgen | 74 | $19,152 |
| Regeneron Healthcare Solutions, Inc. | 38 | $17,715 |
| Sanofi | 17 | $3,859 |
| Novartis | 15 | $2,705 |
| Takeda Pharmaceuticals U.S.A., Inc. | 59 | $1,230 |
| CSL Behring | 32 | $694 |
| Grifols USA, LLC | 28 | $553 |
| GSK | 18 | $274 |
| Veran Medical Technologies, Inc. | 2 | $178 |
| Harmony Biosciences LLC | 8 | $166 |
| Actelion Pharmaceuticals US, Inc. | 7 | $156 |
| Merck | 7 | $143 |
| Vifor Pharma, Inc. | 6 | $128 |
| Johnson & Johnson | 1 | $120 |
| Shire North American Group Inc | 6 | $106 |
| Insmed, Inc. | 7 | $106 |
| United Therapeutics Corporation | 5 | $103 |
| Insulet Corporation | 1 | $100 |
| Pfizer | 5 | $99 |
| Boehringer Ingelheim | 4 | $86 |
| Sunovion Pharmaceuticals Inc. | 3 | $52 |
| Mylan Specialty L.p. | 3 | $40 |
| AbbVie | 1 | $33 |
| Philips North America LLC | 2 | $31 |
| Gilead | 2 | $28 |
| Electromed, Inc. | 1 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Bayer | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $15 |
| Inogen, Inc. | 1 | $14 |
| Advanced Respiratory, Inc | 1 | $13 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
| Pulmonx Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$324,390 in reported general payments places this provider in the 95th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlassiaAlpha-1-Proteinase Inhibitor | 26 | $366,518 |
| TezspireTezepelumab-Ekko | 69 | $278,897 |
| ZemairaAlpha-1-Proteinase Inhibitor | 11 | $206,730 |
| XolairOmalizumab | 70 | $184,645 |
| Qvar RedihalerBeclomethasone Dipropionate | 176 | $75,861 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $38,428 |
| Atrovent HfaIpratropium Bromide | 34 | $18,822 |
| Arnuity ElliptaFluticasone Furoate | 59 | $18,578 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $12,799 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $12,680 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 290 | $12,541 |
| EliquisApixaban | 17 | $9,732 |
| AirsupraAlbuterol Sulfate/Budesonide | 15 | $9,137 |
| Montelukast Sodium | 647 | $9,096 |
| Epinephrine | 31 | $7,409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $1,230 | $366,51826 claims |
| AstraZenecaTezspire, Symbicort, Airsupra | $161,917 | $300,833127 claims |
| CSL BehringZemaira | $694 | $206,73011 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $274 | $57,006107 claims |
| Boehringer IngelheimCombivent Respimat | $86 | $12,68015 claims |
| PfizerEliquis | $99 | $9,73217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Port Huron
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
- Samuel AllenTroy$287K
- Daniel MaxwellAlpena$235K
- Ihab DeebajahGarden City$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.